158 related articles for article (PubMed ID: 11713811)
1. Comparative study of DNA vaccines encoding various antigens against Leishmania mexicana.
Dumonteil E; Andrade-Narvarez F; Escobedo-Ortegon J; Ramirez-Sierra MJ; Valencia-Pacheco G; Flores-Serrano A; Canto-Lara S; Arjona-Torres A
Dev Biol (Basel); 2000; 104():135-41. PubMed ID: 11713811
[TBL] [Abstract][Full Text] [Related]
2. DNA vaccines induce partial protection against Leishmania mexicana.
Dumonteil E; Maria Jesus RS; Javier EO; Maria del Rosario GM
Vaccine; 2003 May; 21(17-18):2161-8. PubMed ID: 12706707
[TBL] [Abstract][Full Text] [Related]
3. Aluminium phosphate potentiates the efficacy of DNA vaccines against Leishmania mexicana.
Rosado-Vallado M; Mut-Martin M; García-Miss Mdel R; Dumonteil E
Vaccine; 2005 Nov; 23(46-47):5372-9. PubMed ID: 16054271
[TBL] [Abstract][Full Text] [Related]
4. CTL responses to Leishmania mexicana gp63-cDNA vaccine in a murine model.
Ali SA; Rezvan H; McArdle SE; Khodadadi A; Asteal FA; Rees RC
Parasite Immunol; 2009 Jul; 31(7):373-83. PubMed ID: 19527453
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
Iborra S; Soto M; Carrión J; Alonso C; Requena JM
Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
[TBL] [Abstract][Full Text] [Related]
6. DNA based vaccination with a cocktail of plasmids encoding immunodominant Leishmania (Leishmania) major antigens confers full protection in BALB/c mice.
Ahmed SB; Touihri L; Chtourou Y; Dellagi K; Bahloul C
Vaccine; 2009 Jan; 27(1):99-106. PubMed ID: 18951941
[TBL] [Abstract][Full Text] [Related]
7. Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge.
Rodríguez-Cortés A; Ojeda A; López-Fuertes L; Timón M; Altet L; Solano-Gallego L; Sánchez-Robert E; Francino O; Alberola J
Vaccine; 2007 Nov; 25(46):7962-71. PubMed ID: 17942199
[TBL] [Abstract][Full Text] [Related]
8. A comparative evaluation of different DNA vaccine candidates against experimental murine leishmaniasis due to L. major.
Ahmed SB; Bahloul C; Robbana C; Askri S; Dellagi K
Vaccine; 2004 Apr; 22(13-14):1631-9. PubMed ID: 15068845
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of a Salmonella typhi CVD 908 candidate vaccine strain expressing the major surface protein gp63 of Leishmania mexicana mexicana.
González CR; Noriega FR; Huerta S; Santiago A; Vega M; Paniagua J; Ortiz-Navarrete V; Isibasi A; Levine MM
Vaccine; 1998; 16(9-10):1043-52. PubMed ID: 9682357
[TBL] [Abstract][Full Text] [Related]
10. Transmission blocking vaccine studies in leishmaniasis: II. Effect of immunisation using Leishmania major derived 63 kilodalton glycoprotein, lipophosphoglycan and whole parasite antigens on the course of L. major infection in BALB/c mice.
Tonui WK; Mbati PA; Anjili CO; Orago AS; Turco SJ; Githure JI; Koech DK
East Afr Med J; 2001 Feb; 78(2):90-2. PubMed ID: 11682953
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of Leishmania donovani.
Gamboa-León R; Paraguai de Souza E; Borja-Cabrera GP; Santos FN; Myashiro LM; Pinheiro RO; Dumonteil E; Palatnik-de-Sousa CB
Vaccine; 2006 May; 24(22):4863-73. PubMed ID: 16635538
[TBL] [Abstract][Full Text] [Related]
12. Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection.
Campbell SA; Alawa J; Doro B; Henriquez FL; Roberts CW; Nok A; Alawa CB; Alsaadi M; Mullen AB; Carter KC
Vaccine; 2012 Feb; 30(7):1357-63. PubMed ID: 22210224
[TBL] [Abstract][Full Text] [Related]
13. Protective immunogenicity of the paraflagellar rod protein 2 of Leishmania mexicana.
Saravia NG; Hazbón MH; Osorio Y; Valderrama L; Walker J; Santrich C; Cortázar T; Lebowitz JH; Travi BL
Vaccine; 2005 Jan; 23(8):984-95. PubMed ID: 15620471
[TBL] [Abstract][Full Text] [Related]
14. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
Zadeh-Vakili A; Taheri T; Taslimi Y; Doustdari F; Salmanian AH; Rafati S
Vaccine; 2004 May; 22(15-16):1930-40. PubMed ID: 15121305
[TBL] [Abstract][Full Text] [Related]
15. Vaccine-induced protection against Leishmania amazonensis is obtained in the absence of IL-12/23p40.
Hernández MX; Barçante TA; Vilela L; Tafuri WL; Afonso LC; Vieira LQ
Immunol Lett; 2006 May; 105(1):38-47. PubMed ID: 16466810
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant effect of Taenia crassiceps glycans against leishmanial antigens in mice infected with Leishmania mexicana.
Dissanayake S; Shahin A; Ameen AM
Mol Immunol; 2005 Aug; 42(12):1495-502. PubMed ID: 15950742
[TBL] [Abstract][Full Text] [Related]
17. Transitory or long-lasting immunity to Leishmania major infection: the result of immunogenicity and multicomponent properties of histone DNA vaccines.
Carrión J; Folgueira C; Alonso C
Vaccine; 2008 Feb; 26(9):1155-65. PubMed ID: 18255202
[TBL] [Abstract][Full Text] [Related]
18. Leishmania mexicana and Leishmania major: attenuation of wild-type parasites and vaccination with the attenuated lines.
Daneshvar H; Coombs GH; Hagan P; Phillips RS
J Infect Dis; 2003 May; 187(10):1662-8. PubMed ID: 12721947
[TBL] [Abstract][Full Text] [Related]
19. Protection against cutaneous leishmaniasis by intranasal vaccination with lipophosphoglycan.
Pinheiro RO; Pinto EF; de Matos Guedes HL; Filho OA; de Mattos KA; Saraiva EM; de Mendonça SC; Rossi-Bergmann B
Vaccine; 2007 Mar; 25(14):2716-22. PubMed ID: 16814903
[TBL] [Abstract][Full Text] [Related]
20. Vaccination of different strains of mice against cutaneous leishmaniosis: usefulness of membrane antigens encapsulated into liposomes by intraperitoneal and subcutaneous administration.
Lezama-Dávila CM
Arch Med Res; 1997; 28(1):47-53. PubMed ID: 9078587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
